PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides

About this update from Pharmather Holdings Ltd

U.S. regulatory momentum in psychedelics and peptides could open new commercial opportunities for PharmaTher's PatchPrint™ automated manufacturing platform and PharmaPatch™ product platform as an attractive solution for compounding pharmacies, hospitals, research institutions, and commercial partners Toronto, Ontario--(Newsfile Corp. - April 20, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on microneedle patch technologies, believes it is well-positioned to benefit from two major U.S. regulatory developments: growing federal support for psychedelic medicine and advancing efforts to restore broader compounding access for select therapeutic peptides. Two major U.S. federal shifts have created a compelling commercial opening for the Company's microneedle patch solutions: A Commercial Opportunity Taking Shape PharmaTher believes growing U.S. regulatory momentum in psychedelics and therapeutic peptides could create a meaningful commercial opportunity for the Company. With PatchPrint™ as its automated microneedle patch manufacturing platform and PharmaPatch™ as its microneedle patch product platform, PharmaTher believes it has built an early position in two emerging high-value markets. The Company has previously reported positive PharmaPatch™ research results with psilocybin, LSD, DMT, and MDMA, completed an IND-enabling pharmacokinetic and tolerability study for its ketamine patch, and identified BPC-157, GHK-Cu, TB-500, and KPV as peptide candidates, supported by U.S. provisional patent application No. 64/034,315. PharmaTher believes that as psychedelic therapies advance and peptide compounding potentially expands, demand could grow for more precise, convenient, and patient-friendly delivery options such as microneedle patches. "We believe the regulatory environment is beginning to open in both psychedelics and peptides, and we have already positioned the Company with PatchPrint™ and PharmaPatch™," said Fabio Chianelli, Chief Executive Officer of PharmaTher. "As momentum builds in both markets, we see a meaningful opportunity to offer practical, patient-friendly, and differentiated microneedle patch solutions." The Commercial Opportunity for PatchPrint™ PatchPrint™ is PharmaTher's proprietary automated tabletop microne...

View stock analysis, news, and events for Pharmather Holdings Ltd